5805-39-0Relevant articles and documents
A simple quinoline-derived fluorescent sensor for the selective and sequential detection of copper(II) and sulfide ions and its application in living-cell imaging
Liu, Haiyang,Wu, Fengxu,Zhang, Bibo,Tan, Chunyan,Chen, Yuzong,Hao, Gefei,Tan, Ying,Jiang, Yuyang
, p. 77508 - 77514 (2016)
A simple amide compound (QLBA), prepared from quinoline-2-carboxylic acid and 2-(1H-benzo[d] imidazol-2-yl)aniline, was synthesized and evaluated as an efficient fluorescence chemosensor for the selective recognition of copper ions (Cu2+). This sensor could detect Cu2+ in CH3OH/HEPPES buffer in a wide pH range (4.0-10.0), with obvious fluorescence quenching. The obtained QLBA-Cu2+ complex could be used as a new cascade sensor for detecting sulfide anions (S2-). The corresponding detection limits were found to be 2.2 × 10-7 M for Cu2+ and 4.6 × 10-7 M for S2-. The sensing mechanisms of QLBA toward Cu2+ were systematically investigated in detail by NMR, HR-MS analysis, and density functional theory (DFT) calculations. In addition, this sensor was verified to be of low cytotoxicity and to have good imaging characteristics for the detection of Cu2+ and further for the recognition of S2- in living cells, suggesting that QLBA was a useful tool for tracking Cu2+ and S2- ions in vivo.
Hydrogen-bonded sheets in 2-(2-aminophenyl)-1H-benzimidazol-3-ium dihydrogen phosphate
Shylaja,Mahendra,Varma,Narasimhamurthy,Rathore
, p. o361-o363 (2008)
The title salt, C13H12N3 +·H2PO4 -, contains a nonplanar 2-(2-amino-phenyl)-1H-benzimidazol-3-ium cation and two different dihydrogen phosphate anions, both situated on twofold rotation axes in the space group C2. The anions are linked by O - H...O hydrogen bonds into chains of R 2 2(8) rings. The anion chains are linked by the cations, via hydrogen-bonding complementarities and electrostatic inter-actions, giving rise to a sheet structure with alternating rows of organic cations and inorganic anions. Comparison of this structure with that of the pure amine reveals that the two compounds generate characteristically different sheet structures. The anion-anion chain serves as a template for the assembly of the cations, suggesting a possible application in the design of solid-state materials.
Anti-cancer activity of two novel heterocyclic compounds through modulation of VEGFR and miR-122 in mice bearing Ehrlich ascites carcinoma
Hazem, Reem M.,Mohamed, Anhar A.,Ghareb, Nagat,Mehanna, Eman T.,Mesbah, Noha M.,Abo-Elmatty, Dina M.,Elgawish, Mohamed Saleh
, (2020/12/02)
Metastasis in breast cancer is a leading cause of mortality among women in many countries. This study investigated the anti-cancer role of benzoimidazoquinazoline and benzimidazotriazin; two novel compounds that were designed, synthesized, structurally elucidated, and biologically evaluated as potent anti-angiogenic agents that act through inhibition of vascular endothelial growth factor receptor-2 (VEGFR2). Breast cancer was induced by inoculation of Ehrlich Ascites Carcinoma (EAC) cells. Seventy swiss albino mice were randomly divided into 7 groups, 10 animals each: (1) normal, (2) control EAC group, (3) cisplatin treated group, (4&5) benzoimidazoquinazoline treated (5 mg/kg and 10 mg/kg), (6&7) benzimidazotriazin treated (5 mg/kg and 10 mg/kg). The expression of miR-122 was assessed in the tumor tissue by quantitative PCR, and the VEGF level was determined in serum by ELISA. VEGFR2 and cluster of differentiation (CD)34 were assessed by immunohistochemistry. Serum ALT, AST, creatinine, and urea were measured. Treatment with benzoimidazoquinazoline and benzimidazotriazin decreased tumor weight and serum levels of VEGF, and down-regulated expression of VEGFR2 and CD34 in the tumor tissue. miR-122 was upregulated, particularly in the benzimidazotriazin (10 mg/kg) group. Relative to cisplatin, the novel compounds were less toxic to kidneys. Benzoimidazoquinazoline and benzimidazotriazin are promising anti-cancer agents that act through inhibition of angiogenesis and thus provide a new strategy for advancement of chemotherapy.
2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES
-
Paragraph 85; 90, (2020/03/02)
A genus of compounds encompassed by formula (III) and their use is disclosed: Formula (III). The compounds activate Ppargc1a and, as a consequence, are useful for treating a variety of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, Huntington's disease, frontotemporal degeneration, dementia with Lewy bodies, motor neuron diseases, and a demyelinating disease.